Stock Taper Q4 2025 Revenue: $821.5 million, a 6.1% increase year-over-year.
Adjusted EBITDA: $99.8 million for Q4; full-year adjusted EBITDA was $608.9 million, slightly above guidance.
Same-Facility Revenue Growth: 4.4% year-over-year, driven by a 1.3% increase in revenue per patient day and a 3.1% increase in patient days.
Start-Up Losses: $12.8 million in Q4, up from $11.2 million in Q4 2024.
CapEx: $93 million in Q4; total of $572 million for 2025, nearly $50 million favorable to prior guidance.
Cash Position: $133.2 million in cash and equivalents, with a net leverage ratio of approximately 4x adjusted EBITDA.
Leadership Transition: Debra Osteen returned as CEO, emphasizing stability, operational discipline, and accountability.
Operational Focus: Prioritizing quality management, enhancing operational execution, and addressing ramp-up issues at new facilities.
Expansion Initiatives: Opened new joint venture facilities with health systems in multiple states and added over 2,500 beds in the last three years, with plans to add 400-600 more beds in 2026.
Quality Improvements: Expanded quality dashboards to track over 50 measures, aiming for better patient outcomes and transparency.
2026 Revenue Guidance: Expected between $3.37 billion and $3.45 billion, with adjusted EBITDA between $575 million and $610 million.
Same-Facility Volume Growth: Anticipated between 0% and 1%, impacted by a 350 basis point headwind from changes in the New York Medicaid program.
Start-Up Losses: Expected to range from $47 million to $53 million in 2026, with a focus on reducing these losses over time.
Q1 2026 Outlook: Revenue expected between $820 million and $830 million, with adjusted EBITDA between $130 million and $137 million.
New York Medicaid Changes: Anticipated $25 million to $30 million annual EBITDA impact due to restrictions on out-of-state care.
Operational Challenges: Some new facilities have not ramped as quickly as expected due to regulatory and staffing issues.
Start-Up Losses: Continued losses from new facilities remain a concern, though expected to improve over time.
Legal and Regulatory Risks: Ongoing government investigations and potential settlements could impact cash flow and leverage.
Value Creation Review: Ongoing focus on identifying short- and long-term value opportunities, with no immediate plans for divestitures.
Volume Growth Expectations: Management believes the long-term growth algorithm remains intact, with strong demand for services.
Referral Relationships: Emphasis on rebuilding trust with referral sources through improved patient outcomes and consistent care quality.
California Staffing Requirements: New regulations expected to have a $4 million EBITDA impact, with ongoing discussions about funding offsets with the state.
Operational Structure Review: Management is assessing corporate and field leadership structures to ensure alignment with operational needs and market demands. Overall, Acadia Healthcare is navigating a transitional phase with a focus on operational excellence, strategic growth, and addressing challenges in the regulatory environment while maintaining a positive outlook for 2026.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT